Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 27Magnetic Resonance Spectroscopy 23pembrolizumab 22Specimen Handling 19Cetuximab 17Nivolumab 14Carboplatin 13Platinum 111,2-diaminocyclohexaneplatinum II citrate 11Radiotherapy, Intensity-Modulated 10Radiotherapy 9Radiation 9Paclitaxel 8Docetaxel 8Biopsy 8Surveys and Questionnaires 6Immunoglobulin G 6Disulfides 6atezolizumab 5Ipilimumab 5Fluorouracil 5dostarlimab 4cemiplimab 4Gemcitabine 4CTLA-4 Antigen 4(225)Ac-DOTA-c(RGDyK) 4toripalimab 3relatlimab 3fludarabine 3cabozantinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
RC48 antibody × Head & Neck × 30 days × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡